Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | THRB | P10828 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 5/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | PLEC | Q15149 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29624960 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4LMNAMAPTTHRB | |
| SCHEMBL8348984 | 0.85 | ALDH1A1 (0.51) | ALDH1A1CYP3A4MAPTTHRBMEN1 | |
| SCHEMBL763435 | 0.84 | ALDH1A1 (0.44) | ALDH1A1CYP3A4LMNAMAPTTHRB | |
| SCHEMBL24732041 | 0.84 | ALDH1A1 (0.47) | ALDH1A1CYP3A4MAPTTHRBMEN1 | |
| SCHEMBL25440381 | 0.82 | ALDH1A1 (0.46) | ALDH1A1CYP3A4LMNAMAPTTHRB | |
| SCHEMBL19312419 | 0.82 | HTR1A (0.47) | ALDH1A1CYP3A4TDP1HTR1AHDAC3 | |
| SCHEMBL2929239 | 0.82 | ALDH1A1 (0.42) | ALDH1A1CYP3A4MAPTTHRBMEN1 | |
| SCHEMBL3897070 | 0.81 | ALDH1A1 (0.47) | ALDH1A1CYP3A4MAPTTHRBMEN1 | |
| SCHEMBL4315483 | 0.81 | NCF1 (0.53) | ALDH1A1LMNAMAPTMEN1KMT2A | |
| SCHEMBL16407615 | 0.81 | PTGER4 (0.49) | ALDH1A1CYP3A4LMNAMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304590-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2025-10-02 | — | — | US | disclosed |
| US-12371436-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2025-07-29 | — | — | US | disclosed |
| US-12037336-B2 | Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) | Enterprise Therapeutics Limited (GB) | 2024-07-16 | — | — | US | disclosed |
| US-20240067653-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2024-02-29 | — | — | US | disclosed |
| US-11739094-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2023-08-29 | — | — | US | disclosed |
| EP-3794002-B1 | COMPOUNDS | ENTERPRISE THERAPEUTICS LTD (GB) | 2023-08-02 | — | — | EP | disclosed |
| CN-110214141-B | Benzodiazolium compounds as ENaC inhibitors | 企业治疗学有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20210188855-A1 | COMPOUNDS | Enterprise Therapeutics Limited (GB) | 2021-06-24 | — | — | US | disclosed |
| EP-3544981-B1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | ENTERPRISE THERAPEUTICS LTD (GB) | 2021-06-23 | — | — | EP | disclosed |
| US-20210147432-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2021-05-20 | — | — | US | disclosed |
| US-9328131-B2 | Benzimidazolium compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-03 | — | — | US | disclosed |
| US-9126985-B2 | Tetra- and pentasubstituted benzimidazolium compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-08 | — | — | US | disclosed |
| US-9126985-B2 | Tetra- and pentasubstituted benzimidazolium compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-08 | — | — | US | disclosed |
| US-9073954-B2 | 5-substituted benzimidazolium compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9073954-B2 | 5-substituted benzimidazolium compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| WO-2015007519-A1 | NOVEL BENZIMIDAZOLIUM COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015007516-A1 | NOVEL 5-SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015007517-A1 | NOVEL TETRA- AND PENTASUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | WO | disclosed |
| WO-2011079087-A1 | ENAC BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079087-A1 | ENAC BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739094-B2 | Substituted benzodiazoliums as ENaC inhibitors | NHERF1, SCNN1B, SCNN1A | ALDH1A1 1058/4885CYP3A4 3207/4885LMNA 2444/4885 |
| US-12371436-B2 | Substituted benzodiazoliums as ENaC inhibitors | NHERF1, SCNN1B, SCNN1A | ALDH1A1 1058/4885CYP3A4 3207/4885LMNA 2444/4885 |
| US-12037336-B2 | Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) | SCNN1B, SCNN1A, SCNN1G | ALDH1A1 1465/4885CYP3A4 3583/4885LMNA 1457/4885 |
| US-20240067653-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | NHERF1, SCNN1B, SCNN1A | ALDH1A1 1179/4885CYP3A4 3139/4885LMNA 2568/4885 |
| US-20210147432-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | NHERF1, SCNN1B, SCNN1A | ALDH1A1 1179/4885CYP3A4 3139/4885LMNA 2568/4885 |
| US-20210188855-A1 | COMPOUNDS | NHERF1, SCNN1B, SCNN1A | ALDH1A1 572/4885CYP3A4 2556/4885LMNA 1964/4885 |
| US-20250304590-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | NHERF1, SCNN1B, SCNN1A | ALDH1A1 1179/4885CYP3A4 3139/4885LMNA 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.